Research programme: subtype-selective NMDA receptor modulators - Cadent Therapeutics

Drug Profile

Research programme: subtype-selective NMDA receptor modulators - Cadent Therapeutics

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jubilant Pharmaceuticals; Mnemosyne Pharmaceuticals
  • Developer Cadent Therapeutics; Luc Therapeutics
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action NMDA receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Schizophrenia
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Brain injuries; Stroke

Most Recent Events

  • 17 Oct 2017 Cadent Therapeutics plans a phase I trial for schizophrenia in 2018
  • 17 Oct 2017 Luc Therapeutics is now called Cadent Therapeutics
  • 06 Mar 2017 Research programme for schizophrenia is underway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top